Genesis Therapeutics

Genesis Therapeutics is a company that has its roots in academic research, which serves as the foundational element of its growing portfolio of AI technologies. The company employs a combination of innovative deep neural networks, biophysical simulation techniques, and highly scalable computing infrastructure. This amalgamation of technologies is geared towards achieving remarkable results in molecular generation and property prediction, particularly in the field of drug discovery and molecular design.

Established in 2019 and headquartered in South San Francisco, California, Genesis Therapeutics focuses on leveraging innovative AI methodologies to enhance the efficiency and accuracy of molecular research. The company's approach holds promise in revolutionizing how molecules are generated and analyzed, potentially leading to advancements in drug development and related fields.

Genesis Therapeutics headquartered in United States, North America, operates in the Information Technology, Biotechnology, Artificial Intelligence (AI) sector. The company focuses on Information Technology and has secured $15.4B in funding across 60 round(s). With a team of 11-50 employees, Genesis Therapeutics is actively contributing to advancements in Information Technology. Their latest funding round, Series B - Genesis Therapeutics, raised $200.0M. Discover more about their projects, partnerships, and impact on our platform.